Pratik Shah - Sep 1, 2023 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DSGN	Stock Option (right to buy)	Award	$0	+1.05M	$0.00	1.05M	Sep 1, 2023	Common Stock	1.05M	$2.48	Direct	F1
transaction	DSGN	Stock Option (right to buy)	Award	$0	+525K	$0.00	525K	Sep 1, 2023	Common Stock	525K	$2.48	Direct	F2
transaction	DSGN	Stock Option (right to buy)	Award	$0	+525K	$0.00	525K	Sep 1, 2023	Common Stock	525K	$2.48	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The shares subject to the option will vest as follows: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.
F2	The shares subject to the option will vest as follows provided that an investigational new drug application for a product candidate for the treatment of Friedrich ataxia ("FA") submitted by the Issuer after September 1, 2023 receives clearance from the U.S. Food and Drug Administration: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.
F3	The shares subject to the option will vest as follows provided that the Company initiates a Phase 2a clinical trial for a product candidate for the treatment of FA: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.